Study 3 of 22Exenatide literatureLancet (London, England) · Phase 3Top journal2026
Expression of Concern: Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial.
Not reported in abstract.
Where it sits
this study against the rest of the exenatide corpus2
Preclinical · this one
12
Observational
0
Open-label
3
Randomised
5
Reviews
Summary and findings
Not reported in abstract.
How much of this paper we could read: title only (0.00). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →
Phase 32026
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Limitations
Not reported in abstract.
Elsewhere in the Exenatide corpus
ANo Heavy Drinking Days and Percentage of Days Abstinent in a Randomized Trial of Adjunctive Ketamine for Alcohol Use Disorder: Secondary Analysis of the KARE Trialbiorxiv-preprint · 2023 · n=96 · 78.5% versus 57.8% days abstinent at weeks 17–24, P = .032HumanBImpact of GLP-1 Analogue Therapy on Gastrointestinal Outcomes in Patients with Irritable Bowel Syndrome: A Real-World TriNetX Analysis.Digestive diseases and sciences · 2023 · n=4668 · 8.9% chronic diarrhea vs 10.6% in non-GLP-1 group at 90 days, p<0.001.HumanBPrescription Sequence Symmetry Analysis of Glucagon-Like Peptide-1 Receptor Agonists and Neuropsychiatric Conditions.Clinical pharmacology and therapeutics · 2026 · n=2033 · aSR: 0.85; 95% CI: 0.76-0.94 for antidepressants initiationHumanCDevelopment of Chondroitin Sulfate ‑ Stabilized PLGA Microspheres of Exenatide via Polarity Gradient Extraction.Pharmaceutical development and technology · 2026 · Drug loading up to 4.7% w/w.AnimalBGlucagon-like Peptide-1 Receptor Agonist-Associated Injection Site and Dermatologic Reactions.Clinics in dermatology · 2026 · n=442567 · 53.1% of skin and injection-site reports for exenatide.reviewCAcute glucagon-like peptide-1 receptor agonist, semaglutide, attenuates cue-, drug-, and stress-induced fentanyl seeking in male Sprague-Dawley rats.Behavioural pharmacology · 2026 · All doses of semaglutide fully prevented drug- and stress-induced reinstatement of fentanyl seeking.Animal